IMB Dx, Inc. (KOSDAQ:461030)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,080
+230 (1.94%)
At close: Dec 5, 2025
14.39%
Market Cap 169.33B
Revenue (ttm) 4.26B
Net Income (ttm) -7.99B
Shares Out 14.02M
EPS (ttm) -569.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,010,621
Average Volume 380,943
Open 12,230
Previous Close 11,850
Day's Range 11,500 - 12,950
52-Week Range 7,180 - 14,430
Beta n/a
RSI 67.10
Earnings Date n/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 461030
Full Company Profile

Financial Performance

In 2024, IMB Dx's revenue was 3.41 billion, a decrease of -15.40% compared to the previous year's 4.03 billion. Losses were -9.58 billion, -8.06% less than in 2023.

Financial Statements

News

There is no news available yet.